Chemodex

Rutin

CHF 108.00
In stock
CDX-R0400-M05050 mgCHF 108.00
More Information
Product Details
Synonyms Rutoside; Phytomelin; Sophorin; Birutan; Eldrin; Birutan Forte; Rutin trihydrate; Globularicitrin; Violaquercitrin; Quercetin rutinoside
Product Type Chemical
Properties
Formula

C27H30O16

MW 610.52
CAS 153-18-4
RTECS VM2975000
Purity Chemicals ≥95% (HPLC)
Appearance Pale yellow powder.
Solubility Soluble in DMSO.
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key IKGXIBQEEMLURG-NVPNHPEKSA-N
Smiles O=C1C2=C(O)C=C(O)C=C2OC(C3=CC(O)=C(O)C=C3)=C1O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]5[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O5)O4
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at RT.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

A polyphenolic flavonoid that acts as an antioxidant and NO scavenger. It can attenuate peroxide production in glial cells by acting as a free radical scavenger and protect renal cells from oxidative injury. Inclusion of rutin in the diet of rats significantly reduced the appearance of single-strand breaks in nuclear DNA caused by hepatocarcinogens aflatoxin B1 and N-nitrosodiumethylamine. This protection from DNA damage was found to be due to a reduction in the induction of repair enzymes polymerase, DNA polymerase β and DNA ligase. Since DNA damage and inefficient repair are thought to initiate the process of carcinogenesis, effects of rutin on these functions suggests a protective role of this flavonoid against carcinogenesis induced by chemical carcinogens. Rutin ameliorates obesity through brown fat activation.

Product References

(1) I.B. Afanas'ev, et al.; Biochem. Pharmacol. 38, 1763 (1989) | (2) R.P. Webster, et al.; Cancer Lett. 109, 185 (1996) | (3) E.A. Ostrakhovitch & I.B. Afanas'ev; Biochem. Pharmacol. 62, 743 (2001) | (4) N. Kamalakkannan & P.S. Prince; Basic Clin. Pharmacol. Toxicol. 98, 97 (2006) | (5) J.P. Lin, et al.; Leuk. Res. 33, 823 (2009) | (6) R. Lapa Fda, et al.; J. Pharm. Pharmacol. 63, 875 (2011) | (7) S.W. Wang, et al.; Neurotoxicology 33, 482 (2012) | (8) X. Yuan, et al.; FASEB J. 31, 333 (2016)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.